Direkt zum Inhalt
Merck

Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review).

Acta physiologica Hungarica (2014-12-24)
Asghar Ghasemi, S Khalifi, S Jedi
ZUSAMMENFASSUNG

Diabetes is one of the five leading causes of death in the world, with type 2 diabetes occurring more frequently than type 1. Management of diabetes without side effects is still a challenge and therefore new strategies need to be examined. Because of difficulties in human research, animal models of diabetes are useful research tools for this purpose and rodent models of type 2 diabetes are the first choice. The aim of this study is an overview on one of the most frequently used models of type 2 diabetes in rat, induced by streptozotocin and nicotinamide, considering its advantages and disadvantages for diabetes research in humans.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Streptozocin, ≥75% α-anomer basis, ≥98% (HPLC), powder
Sigma-Aldrich
Nicotinamid, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Nicotinamid, ≥99.5% (HPLC)
Supelco
Niacinamid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Nicotinamid, ≥98% (HPLC), powder
USP
Niacinamid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Niacinamid, meets USP testing specifications
Supelco
Nicotinamid (Vitamin B3) -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Nicotinamid, ≥98.5% (HPLC)
Nicotinamid, European Pharmacopoeia (EP) Reference Standard